JP4188839B2 - ホスファターゼインヒビーターとしてのピリミドトリアジン - Google Patents

ホスファターゼインヒビーターとしてのピリミドトリアジン Download PDF

Info

Publication number
JP4188839B2
JP4188839B2 JP2003556413A JP2003556413A JP4188839B2 JP 4188839 B2 JP4188839 B2 JP 4188839B2 JP 2003556413 A JP2003556413 A JP 2003556413A JP 2003556413 A JP2003556413 A JP 2003556413A JP 4188839 B2 JP4188839 B2 JP 4188839B2
Authority
JP
Japan
Prior art keywords
ylmethyl
diamine
pyrimido
triazine
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003556413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005517677A5 (enExample
JP2005517677A (ja
Inventor
ガーティン，ケビン・リチャード
セッティ，リナ・クアットロッチオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2005517677A publication Critical patent/JP2005517677A/ja
Publication of JP2005517677A5 publication Critical patent/JP2005517677A5/ja
Application granted granted Critical
Publication of JP4188839B2 publication Critical patent/JP4188839B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
JP2003556413A 2001-12-27 2002-12-27 ホスファターゼインヒビーターとしてのピリミドトリアジン Expired - Fee Related JP4188839B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34393701P 2001-12-27 2001-12-27
US39911002P 2002-07-26 2002-07-26
PCT/EP2002/014771 WO2003055883A1 (en) 2001-12-27 2002-12-27 Pyrimidotriazines as phosphatase inhibitors

Publications (3)

Publication Number Publication Date
JP2005517677A JP2005517677A (ja) 2005-06-16
JP2005517677A5 JP2005517677A5 (enExample) 2005-12-22
JP4188839B2 true JP4188839B2 (ja) 2008-12-03

Family

ID=26993696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003556413A Expired - Fee Related JP4188839B2 (ja) 2001-12-27 2002-12-27 ホスファターゼインヒビーターとしてのピリミドトリアジン

Country Status (19)

Country Link
US (1) US6642381B2 (enExample)
EP (1) EP1467996B1 (enExample)
JP (1) JP4188839B2 (enExample)
KR (1) KR100601769B1 (enExample)
CN (1) CN100402530C (enExample)
AT (1) ATE311388T1 (enExample)
AU (1) AU2002367190B2 (enExample)
BR (1) BR0215395A (enExample)
CA (1) CA2471265C (enExample)
DE (1) DE60207759T2 (enExample)
ES (1) ES2252554T3 (enExample)
JO (1) JO2242B1 (enExample)
MX (1) MXPA04006266A (enExample)
PA (1) PA8562901A1 (enExample)
PE (1) PE20030896A1 (enExample)
PL (1) PL371180A1 (enExample)
TW (1) TW200306313A (enExample)
UY (1) UY27606A1 (enExample)
WO (1) WO2003055883A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1439834A1 (en) * 2001-10-30 2004-07-28 Applied Research Systems ARS Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
PL377620A1 (pl) 2002-11-18 2006-02-06 F. Hoffmann-La Roche Ag Diazynopirymidyny
US20040186151A1 (en) * 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
AU2004210711B2 (en) * 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
WO2005080346A1 (en) * 2004-02-12 2005-09-01 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP1991544B1 (en) * 2006-01-30 2018-08-15 vTv Therapeutics LLC Substituted imidazole derivatives and their use as ptpase inhibitors
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010083645A1 (en) * 2009-01-21 2010-07-29 Shanghai Targetdrug Co., Ltd PYRIMIDO[5,4-e][1,2,4]TRIAZINES AND USES THEREOF
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
KR20150127599A (ko) 2013-03-15 2015-11-17 모치다 세이야쿠 가부시키가이샤 비알코올성 지방간염을 치료하기 위한 조성물 및 방법
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
GB0022079D0 (en) 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor

Also Published As

Publication number Publication date
ES2252554T3 (es) 2006-05-16
PA8562901A1 (es) 2003-07-28
DE60207759D1 (de) 2006-01-05
DE60207759T2 (de) 2006-08-03
EP1467996A1 (en) 2004-10-20
CA2471265A1 (en) 2003-07-10
TW200306313A (en) 2003-11-16
JO2242B1 (en) 2004-10-07
BR0215395A (pt) 2004-12-07
JP2005517677A (ja) 2005-06-16
KR20040068981A (ko) 2004-08-02
PE20030896A1 (es) 2003-11-05
ATE311388T1 (de) 2005-12-15
WO2003055883A1 (en) 2003-07-10
CN1610683A (zh) 2005-04-27
KR100601769B1 (ko) 2006-07-19
EP1467996B1 (en) 2005-11-30
US6642381B2 (en) 2003-11-04
AU2002367190B2 (en) 2006-10-05
UY27606A1 (es) 2003-06-30
US20030153756A1 (en) 2003-08-14
PL371180A1 (en) 2005-06-13
AU2002367190A1 (en) 2003-07-15
MXPA04006266A (es) 2004-09-27
CA2471265C (en) 2010-02-09
CN100402530C (zh) 2008-07-16

Similar Documents

Publication Publication Date Title
JP2005517677A (ja) ホスファターゼインヒビーターとしてのピリミドトリアジン
JP4184378B2 (ja) ジペプチジルペプチダーゼｉｖを阻害する化合物
EP0203721A2 (en) 8-Phenyl xanthines
HU209305B (en) Process for producing 1h-imidazo(4,5-b)quinolinyl oxyalkanecarboxylic acid amides having increased water solubility, as well as pharmaceutical compositions comprising same
HUP0203225A2 (hu) Benzodiazepinszármazékok, előállításuk és alkalmazásuk
WO1999048887A1 (en) Imidazolone anorectic agents: iii. heteroaryl derivatives
TW200404803A (en) Novel use
US6964960B2 (en) Indoloquinazolinones
US8188133B2 (en) Imidazole derivatives, preparation and user thereof as medicine
US7098220B2 (en) Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same
JP2544939B2 (ja) ベンゾヘテロ環誘導体
US4840948A (en) 1-(hydroxystyrl)-5H-2,3-benzodiazepine derivatives, and pharmaceutical compositions containing the same
US7125997B2 (en) Differential tumor cytotoxicity compounds and compositions
US6077841A (en) 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
US7226915B2 (en) Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
RU2289583C2 (ru) Пиримидотриазины, способ их получения, фармацевтическая композиция на их основе и применение
JP4567889B2 (ja) （（アミノイミノメチル）アミノ）アルカンカルボキシアミドおよび治療におけるその適用
CN1083842C (zh) [1,2,4]三唑并[4,3－a]喹喔啉酮衍生物,其制备和用途
EP0725776B1 (en) 3-aryl-4-alkyl and 4,5-dialkyl-4h-1,2,4-triazoles useful as memory enhancers
US5326870A (en) Substituted sulfonamide derivative and a pharmaceutical composition comprising the same
CN100334088C (zh) 作为蛋白质酪氨酸磷酸酶抑制剂的二氨基吡咯并喹唑啉化合物
JPH11140086A (ja) ４−置換−１Ｈ−６−オキソピラゾロ［３，４−ｄ］ピリミジン化合物及びキサンチンオキシダーゼ阻害剤
WO2023072966A1 (en) Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
CN120329285A (zh) 一种pi3k抑制剂及其用途

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080909

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080911

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110919

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees